FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328292818> ?p ?o ?g. }

• W2328292818 abstract "You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Peyronie's Disease1 Apr 2014PD22-01 DETERMINING THE FEASIBILITY OF USING STEM CELLS TO TREAT ERECTILE DYSFUNCTION IN HUMANS Michael Zahalsky, Melissa Marchand, Leanne Iorio, Walquiria Cassini, and Lauren Pomerantz Michael ZahalskyMichael Zahalsky More articles by this author , Melissa MarchandMelissa Marchand More articles by this author , Leanne IorioLeanne Iorio More articles by this author , Walquiria CassiniWalquiria Cassini More articles by this author , and Lauren PomerantzLauren Pomerantz More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1852AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Stem cell therapy is thought to improve wound healing and promote vasculogenesis. Erectile Dysfunction (ED) is largely from microvascular disease such as diabetes and hypertension. This study seeks to evaluate the feasibility and effects of intracavernosal injection of Placental Matrix derived Mesenchymal Stem Cells (PM-MSCs) for the treatment of ED. METHODS After obtaining Western IRB approval, patients with ED were screened with the International Index of Erectile Function (IIEF). We excluded post prostatectomy patients. Once patients were selected they underwent informed consent and Doppler Ultrasound of their penises pre and post injection with 0.2cc of Trimix for standardization of results. Measurements were obtained for Peak systolic Velocity (PSV) and End Diastolic Velocity (EDV), stretched penile length (SPL) pre-injection, and width post-injection of trimix. On a separate visit, 1 cc of PM-MSCs was diluted with 2 cc of isotonic saline to a total of 3 cc. Next, 1.5 cc was injected into each corpora at the base of the penis. The product injected is a placental stem cell product that mixes mesenchymal stem cells with growth factors and cytokines and an extracellular matrix to promote wound healing, angiogenesis, and tissue repair. At 6 weeks and 3 months patients were reevaluated pre and post injection of trimix. RESULTS There are 7 patients that have been injected with PM-MSCs with 6 week follow up. Follow up data at 3 months exists for 3 patients. At 6 weeks, all 7 patients’ PSV post trimix injection increased (5.4% - 70.2%). All patients’ SPL increased (1.3% to 7.1 %) and all patients’ penile width increased (1.6%-23.8%). All 7 patients were happy they had the treatment, and 2 patients that had previously failed all oral therapies were now getting erections on their own. At 3 months, PSV post trimix injection had increased in all 3 patients (28.4% - 52.1%) Using unpaired t-tests, this was statistically significant with a p < 0.05. EDV post trimix increased in 2 patients achieving statistical significance ( p < 0.05). At 3 months, 1 additional patient was now able to achieve erections on his own. IIEF increased in all of these patients (21.4% -36.8%). There were no reported complications. CONCLUSIONS This is one of the first studies to evaluate the ability and effects of using Stem Cells to treat erectile dysfunction. Although the sample size is small, the results are very promising. PM-MSCs needs to be evaluated further to determine their ability to repair the Corpora Cavernosum and assist patients in achieving erections. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e671-e672 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Michael Zahalsky More articles by this author Melissa Marchand More articles by this author Leanne Iorio More articles by this author Walquiria Cassini More articles by this author Lauren Pomerantz More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2328292818 created "2016-06-24" @default.
• W2328292818 creator A5004618466 @default.
• W2328292818 creator A5027949999 @default.
• W2328292818 creator A5062635804 @default.
• W2328292818 creator A5069049198 @default.
• W2328292818 creator A5069879184 @default.
• W2328292818 date "2014-04-01" @default.
• W2328292818 modified "2023-09-27" @default.
• W2328292818 title "PD22-01 DETERMINING THE FEASIBILITY OF USING STEM CELLS TO TREAT ERECTILE DYSFUNCTION IN HUMANS" @default.
• W2328292818 doi "https://doi.org/10.1016/j.juro.2014.02.1852" @default.
• W2328292818 hasPublicationYear "2014" @default.
• W2328292818 type Work @default.
• W2328292818 sameAs 2328292818 @default.
• W2328292818 citedByCount "0" @default.
• W2328292818 crossrefType "journal-article" @default.
• W2328292818 hasAuthorship W2328292818A5004618466 @default.
• W2328292818 hasAuthorship W2328292818A5027949999 @default.
• W2328292818 hasAuthorship W2328292818A5062635804 @default.
• W2328292818 hasAuthorship W2328292818A5069049198 @default.
• W2328292818 hasAuthorship W2328292818A5069879184 @default.
• W2328292818 hasConcept C126322002 @default.
• W2328292818 hasConcept C126894567 @default.
• W2328292818 hasConcept C141071460 @default.
• W2328292818 hasConcept C142724271 @default.
• W2328292818 hasConcept C198826908 @default.
• W2328292818 hasConcept C2777572544 @default.
• W2328292818 hasConcept C2779929075 @default.
• W2328292818 hasConcept C28328180 @default.
• W2328292818 hasConcept C3020768380 @default.
• W2328292818 hasConcept C54355233 @default.
• W2328292818 hasConcept C71924100 @default.
• W2328292818 hasConcept C86803240 @default.
• W2328292818 hasConceptScore W2328292818C126322002 @default.
• W2328292818 hasConceptScore W2328292818C126894567 @default.
• W2328292818 hasConceptScore W2328292818C141071460 @default.
• W2328292818 hasConceptScore W2328292818C142724271 @default.
• W2328292818 hasConceptScore W2328292818C198826908 @default.
• W2328292818 hasConceptScore W2328292818C2777572544 @default.
• W2328292818 hasConceptScore W2328292818C2779929075 @default.
• W2328292818 hasConceptScore W2328292818C28328180 @default.
• W2328292818 hasConceptScore W2328292818C3020768380 @default.
• W2328292818 hasConceptScore W2328292818C54355233 @default.
• W2328292818 hasConceptScore W2328292818C71924100 @default.
• W2328292818 hasConceptScore W2328292818C86803240 @default.
• W2328292818 hasIssue "4S" @default.
• W2328292818 hasLocation W23282928181 @default.
• W2328292818 hasOpenAccess W2328292818 @default.
• W2328292818 hasPrimaryLocation W23282928181 @default.
• W2328292818 hasRelatedWork W2143580412 @default.
• W2328292818 hasRelatedWork W2332341289 @default.
• W2328292818 hasRelatedWork W2487410597 @default.
• W2328292818 hasRelatedWork W2737074673 @default.
• W2328292818 hasRelatedWork W2794422718 @default.
• W2328292818 hasRelatedWork W3033078393 @default.
• W2328292818 hasRelatedWork W4206370751 @default.
• W2328292818 hasRelatedWork W4237985843 @default.
• W2328292818 hasRelatedWork W4238070260 @default.
• W2328292818 hasRelatedWork W4251431979 @default.
• W2328292818 hasVolume "191" @default.
• W2328292818 isParatext "false" @default.
• W2328292818 isRetracted "false" @default.
• W2328292818 magId "2328292818" @default.
• W2328292818 workType "article" @default.